Lilly rides Mounjaro, Zepbound to better
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles
Israeli army says it kills over 130 militants in E. Rafah
JERUSALEM, May 18 (Xinhua) -- The Israel Defense Forces (IDF) have killed more than 130 militants in2024-05-21Multinational enterprises confident of China's economic growth target
(ECNS) -- Against the backdrop of sluggish global economic growth, China's anticipation of a growth2024-05-21Xi Focus: CPC Leadership Meeting Calls for Rallying Powerful Force to Advance National Rejuvenation
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-21Israel cancels indoor mask requirement
People visit a shopping mall in central Israeli city of Modiin, on April 24, 2022. The decision to c2024-05-21Hilarious moment mother asks her Cocker Spaniel to help choose her lottery numbers
This is the hilarious moment a woman enlisted the help of her Cocker Spaniel to help choose her lott2024-05-21U.S. stocks fall as investors dump risky assets amid surging inflation
Traders work at the New York Stock Exchange (NYSE) in New York, the United States, June 13, 2022. U.2024-05-21
atest comment